Vicinitas Therapeutics
San Francisco-based Vicinitas Therapeutics, a biotech startup, develops impactful medicines using its proprietary DUBTAC platform.
Founded
2022San Francisco-based Vicinitas Therapeutics, a biotech startup, develops impactful medicines using its proprietary DUBTAC platform.
Vicinitas Therapeutics, founded in San Francisco, California, is a biotech startup dedicated to developing transformative medicines. The company's core mission is to leverage its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease, thereby providing therapeutic benefits. Vicinitas focuses on creating next-generation treatments that significantly impact patient lives.
Notable figures affiliated with Vicinitas Therapeutics include leading scientists and industry experts, although specific names are not provided. The company has attracted significant attention from investors in the biotech sector due to its innovative approach and potential for high-impact therapies. Vicinitas's key achievements include advancing its DUBTAC platform and making strides in drug development, positioning itself as a promising player in the biotech industry.
Companies similar to Vicinitas Therapeutics include Entact Bio, Vetica Labs, Montara Therapeutics and Deep Apple Therapeutics.
Vicinitas Therapeutics was founded in 2022.
Vicinitas Therapeutics' headquarters is located in San Francisco, CA, US.
Vicinitas Therapeutics' most recent funding round was for $65M (USD) in July 2022.
As of Jul 28, 2022, Vicinitas Therapeutics has disclosed funding of $65M (USD). Undisclosed round amounts are excluded.
Vicinitas Therapeutics has 23 employees as of Feb 4, 2024.
Deep Apple Therapeutics
deepappletx.com
